Bloomage BioTechnology Corporation Limited's (SHSE:688363) Largest Shareholders Are Private Equity Firms With 66% Ownership, Individual Investors Own 17%
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Largest Shareholders Are Private Equity Firms With 66% Ownership, Individual Investors Own 17%
To get a sense of who is truly in control of Bloomage BioTechnology Corporation Limited (SHSE:688363), it is important to understand the ownership structure of the business. We can see that private equity firms own the lion's share in the company with 66% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
And individual investors on the other hand have a 17% ownership in the company.
Let's delve deeper into each type of owner of Bloomage BioTechnology, beginning with the chart below.
Check out our latest analysis for Bloomage BioTechnology
SHSE:688363 Ownership Breakdown December 19th 2022What Does The Institutional Ownership Tell Us About Bloomage BioTechnology?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
We can see that Bloomage BioTechnology does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Bloomage BioTechnology's earnings history below. Of course, the future is what really matters.
SHSE:688363 Earnings and Revenue Growth December 19th 2022Hedge funds don't have many shares in Bloomage BioTechnology. The company's largest shareholder is Huaxi Xinyu Investment Co., Ltd., with ownership of 59%. This implies that they have majority interest control of the future of the company. In comparison, the second and third largest shareholders hold about 7.2% and 1.6% of the stock.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Bloomage BioTechnology
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
We can see that insiders own shares in Bloomage BioTechnology Corporation Limited. It is a very large company, and board members collectively own CN¥1.7b worth of shares (at current prices). we sometimes take an interest in whether they have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 17% stake in Bloomage BioTechnology. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Equity Ownership
With a stake of 66%, private equity firms could influence the Bloomage BioTechnology board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Bloomage BioTechnology has 1 warning sign we think you should be aware of.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
為了弄清誰真正控制了Bloomage生物技術有限公司(上海證券交易所股票代碼:688363),瞭解該企業的所有權結構是很重要的。我們可以看到,私募股權公司以66%的股權擁有該公司的最大份額。換句話説,該集團面臨着最大的上行潛力(或下行風險)。
另一方面,個人投資者擁有該公司17%的股份。
讓我們從下面的圖表開始,更深入地研究Bloomage生物技術的每一種類型的所有者。
查看我們對Bloomage生物技術的最新分析
上海證交所:688363所有權明細2022年12月19日關於Bloomage生物技術,機構所有權告訴了我們什麼?
機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這隻股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。
我們可以看到,Bloomage生物技術確實有機構投資者;他們持有公司很大一部分股票。這可以表明該公司在投資界具有一定的公信力。然而,最好警惕依賴機構投資者帶來的所謂驗證。他們也一樣,有時也會犯錯。如果多家機構同時改變對一隻股票的看法,你可能會看到股價迅速下跌。因此,下面是Bloomage生物技術公司的盈利歷史,值得一看。當然,未來才是真正重要的。
上海證交所:688363收益和收入增長2022年12月19日對衝基金在Bloomage生物技術公司的股份並不多。該公司第一大股東為華西鑫宇投資有限公司,持股59%。這意味着他們對公司的未來擁有多數股權控制。相比之下,第二大和第三大股東分別持有約7.2%和1.6%的股份。
雖然研究一家公司的機構所有權數據是有意義的,但研究分析師的情緒以瞭解風向也是有意義的。有很多分析師在追蹤這隻股票,所以他們的預測可能也是值得的。
Bloomage生物技術的內部所有權
公司內部人的定義可能是主觀的,而且在不同的司法管轄區之間確實有所不同。我們的數據反映了個別內部人士,至少捕捉到了董事會成員。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
我們可以看到,內部人士持有Bloomage生物技術有限公司的股份。這是一家非常大的公司,董事會成員總共擁有價值17億元人民幣的股票(按當前價格計算)。我們有時會對他們一直在買入還是賣出感興趣。
一般公有制
公眾通常是個人投資者,他們持有Bloomage生物技術公司17%的股份。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
私募股權所有權
私募股權公司持有66%的股份,可能會影響Bloomage生物技術董事會。一些人可能會喜歡這樣,因為私人股本有時是讓管理層承擔責任的積極分子。但在其他時候,私募股權公司讓公司上市後,它們的股票都賣光了。
接下來的步驟:
我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。以風險為例-Bloomage生物技術已經1個警告標誌我們認為你應該意識到。
如果你像我一樣,你可能會想一想這家公司是會增長還是會萎縮。幸運的是,您可以查看這份顯示分析師對其未來預測的免費報告。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧